🇧🇪 ARGX.BR — argenx SE

Salud Compra fuerte
← Volver

Precio actual

815,80 EUR

Máx. histórico

912,40

64 días

Caída desde máximo

-10,59%

Rango 52 semanas

568,40 – 925,00

Variación hoy

+0,03%

Cierre anterior

815,60

Rango de hoy

788,80 – 815,80

Volumen hoy

102.849

Peor caída histórica

-39,26%

21/07/2023 → 21/12/2023

Recuperado en 262 días

Volatilidad anualizada ⓘ

43,77%

Información
Nombre completo
argenx SE
Divisa
EUR
Mercado
Brussels
Sector
Salud
Industria
Biotechnology
Empleados
1.863
PER ⓘ
32,83 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
1.005,32 EUR (puede no estar actualizado)
Primera cotización
10/07/2014
Precio actualizado
hace 1 día
Sobre la empresa

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
01/06/2018 82,60 82,70 80,60 80,90 -2,06% 2,54% 11.378
31/05/2018 82,00 83,90 80,90 82,60 +0,61% 3,66% 15.914
30/05/2018 80,90 82,30 80,50 82,10 +0,49% 2,22% 17.561
29/05/2018 82,00 82,10 79,70 81,70 -0,24% 2,93% 23.489
28/05/2018 84,00 84,20 81,60 81,90 -2,73% 3,10% 19.062
25/05/2018 83,10 84,30 82,80 84,20 +3,31% 1,81% 26.636
24/05/2018 81,60 82,10 79,60 81,50 +0,74% 3,06% 16.190
23/05/2018 79,60 82,30 78,00 80,90 +0,12% 5,40% 21.315
22/05/2018 83,00 83,00 79,70 80,80 -1,82% 3,98% 23.347
21/05/2018 81,00 83,70 80,80 82,30 +2,49% 3,58% 39.510
18/05/2018 81,00 81,50 79,80 80,30 -0,62% 2,10% 32.037
17/05/2018 78,30 81,10 78,20 80,80 +4,66% 3,70% 51.456
16/05/2018 78,00 78,00 76,10 77,20 +0,26% 2,44% 48.463
15/05/2018 75,90 77,60 75,90 77,00 +1,58% 2,24% 22.577
14/05/2018 76,00 76,90 74,70 75,80 +0,00% 2,89% 33.131
11/05/2018 78,00 78,00 74,50 75,80 -0,13% 4,49% 16.595
10/05/2018 74,70 78,30 74,60 75,90 +1,61% 4,95% 33.335
09/05/2018 72,10 74,90 70,50 74,70 +1,63% 6,10% 237.652
08/05/2018 73,50 74,10 71,90 73,50 +0,68% 2,99% 19.672
07/05/2018 73,30 73,80 72,00 73,00 -0,68% 2,46% 19.416
04/05/2018 72,30 74,00 69,80 73,50 +1,66% 5,81% 32.835
03/05/2018 72,90 72,90 71,20 72,30 -0,96% 2,33% 9.685
02/05/2018 73,10 74,50 72,90 73,00 -0,14% 2,19% 19.027
30/04/2018 71,00 73,10 70,70 73,10 +3,39% 3,38% 8.608
27/04/2018 71,50 72,90 70,50 70,70 -1,67% 3,36% 19.891
26/04/2018 71,30 72,40 70,50 71,90 +0,84% 2,66% 50.307
25/04/2018 71,30 71,30 69,50 71,30 -0,83% 2,52% 23.395
24/04/2018 72,50 73,00 71,40 71,90 -0,28% 2,21% 18.002
23/04/2018 73,10 74,70 71,10 72,10 +0,84% 4,92% 25.618
20/04/2018 71,70 72,50 70,90 71,50 +0,70% 2,23% 31.831